109 related articles for article (PubMed ID: 6546815)
1. Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol.
Kluft C; Bertina RM; Preston FE; Malia RG; Blamey SL; Lowe GD; Forbes CD
Thromb Res; 1984 Feb; 33(3):297-304. PubMed ID: 6546815
[TBL] [Abstract][Full Text] [Related]
2. Plasma beta-thromboglobulin, fibrinopeptide A and B beta 15-42 antigen in relation to postoperative DVT, malignancy and stanozolol treatment.
Douglas JT; Blamey SL; Lowe GD; Carter DC; Forbes CD
Thromb Haemost; 1985 Apr; 53(2):235-8. PubMed ID: 2410995
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Sue-Ling HM; Davies JA; Prentice CR; Verheijen JH; Kluft C
Thromb Haemost; 1985 Feb; 53(1):141-2. PubMed ID: 3873118
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hereditary protein C deficiency with stanozolol.
Broekmans AW; Conard J; van Weyenberg RG; Horellou MH; Kluft C; Bertina RM
Thromb Haemost; 1987 Feb; 57(1):20-4. PubMed ID: 3590078
[TBL] [Abstract][Full Text] [Related]
5. Protein C antigen levels in major abdominal surgery: relationships to deep vein thrombosis, malignancy and treatment with stanozolol.
Blamey SL; Lowe GD; Bertina RM; Kluft C; Sue-Ling HM; Davies JA; Forbes CD
Thromb Haemost; 1985 Oct; 54(3):622-5. PubMed ID: 3911479
[TBL] [Abstract][Full Text] [Related]
6. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery.
Blamey SL; McArdle BM; Burns P; Carter DC; Lowe GD; Forbes CD
Thromb Haemost; 1984 Feb; 51(1):71-4. PubMed ID: 6539002
[TBL] [Abstract][Full Text] [Related]
7. The effect of intramuscular stanozolol on fibrinolysis and blood lipids.
Small M; McArdle BM; Lowe GD; Forbes CD; Prentice CR
Thromb Res; 1982 Oct; 28(1):27-36. PubMed ID: 6891506
[TBL] [Abstract][Full Text] [Related]
8. Prevention of fibrinolytic shut-down after major surgery by intramuscular stanozolol.
Blamey SL; McArdle BM; Burns P; Lowe GD; Forbes CD; Carter DC; Prentice CR
Thromb Res; 1983 Aug; 31(3):451-9. PubMed ID: 20218001
[TBL] [Abstract][Full Text] [Related]
9. Treatment with stanozolol of type I protein C deficiency in an Italian family.
Mannucci PM; Bottasso B; Sharon C; Tripodi A
Ric Clin Lab; 1984; 14(4):673-80. PubMed ID: 6549220
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis of recurrent venous thrombosis with long-term enhancement of fibrinolysis.
Bielawiec M; Lukjan H; Myśliwiec M; Dabrowski S
Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):971-6. PubMed ID: 94894
[TBL] [Abstract][Full Text] [Related]
11. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults.
Kluft C; Preston FE; Malia RG; Bertina RM; Wijngaards G; Greaves M; Verheijen JH; Dooijewaard G
Thromb Haemost; 1984 Apr; 51(2):157-64. PubMed ID: 6740547
[TBL] [Abstract][Full Text] [Related]
12. The effect of fibrinolytic stimulation by stanozolol on postoperative pulmonary complications.
Cuschieri RJ; Morran CG; Lowe GD; Blamey SL; Forbes CD; McArdle CS
Haemostasis; 1985; 15(5):353-6. PubMed ID: 4076841
[TBL] [Abstract][Full Text] [Related]
13. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol.
Belch JJ; Madhok R; McArdle B; McLaughlin K; Kluft C; Forbes CD; Sturrock RD
Q J Med; 1986 Jan; 58(225):19-27. PubMed ID: 3517926
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement.
Jarrett PE; Morland M; Browse NL
Br Med J; 1977 Apr; 1(6066):933-4. PubMed ID: 856391
[TBL] [Abstract][Full Text] [Related]
15. Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia.
Greer IA; Greaves M; Madhok R; McLoughlin K; Porter N; Lowe GD; Preston FE; Forbes CD
Thromb Haemost; 1985 Jun; 53(3):386-9. PubMed ID: 3931287
[TBL] [Abstract][Full Text] [Related]
16. Treatment with stanozolol before thrombolysis in patients with arterial occlusions.
Noll G; Lämmle B; Duckert F
Thromb Res; 1985 Feb; 37(4):529-32. PubMed ID: 3983908
[TBL] [Abstract][Full Text] [Related]
17. Transient ischemic attack in a patient with congenital protein-C deficiency during treatment with stanozolol.
De Stefano V; Leone G; Teofili L; Ferrelli R; Pollari G; Antonini V; Bizzi B
Am J Hematol; 1988 Oct; 29(2):120-1. PubMed ID: 3189300
[TBL] [Abstract][Full Text] [Related]
18. Clinical investigations on long-term activation of fibrinolysis by anabolic steroids.
Bielawiec M; Bodzenta A; Lukjan H; Kiersnowska-Rogowska B; Kłoczko J; Myśliwiec M; Dabrowski S; Tymiński W; Czestochowska E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):223-9. PubMed ID: 2427405
[TBL] [Abstract][Full Text] [Related]
19. The effect of stanozolol on 15nitrogen retention in the dog.
Olson ME; Morck DW; Quinn KB
Can J Vet Res; 2000 Oct; 64(4):246-8. PubMed ID: 11041505
[TBL] [Abstract][Full Text] [Related]
20. The effect of phenformin plus stanozolol on fibrinolysis, platelet adhesiveness and blood lipids in patients with recurrent venous thrombosis.
Bielawiec M; Myśliwiec M; Perzanowski A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(3):483-8. PubMed ID: 4139068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
